H. Lundbeck A/S announced the presentation of new data from the clinical phase III program of Lu AA21004, an investigational compound for the treatment of adult patients with major depressive disorder (MDD), at the 2011 Annual Meeting of the American Psychiatric Association (APA) in Honolulu, Hawaii. The presentations included results from four placebo-controlled clinical phase III studies as well as pre-clinical data. “The data from the phase III studies continue to support Lu AA21004 as a multimodal anti-depressant based on its safety, efficacy as well as its relapse prevention profile”, says Executive Vice President Anders Gersel Pedersen, Head of Drug Development at Lundbeck, and continues: “With the ongoing development programme of Lu AA21004, we are building on Lundbeck’s market leadership position and our commitment to advancing medical treatment for one of the most prevalent and debilitating psychiatric disorders.”
The annual meeting of the APA is one of the largest scientific meetings for psychiatrists and other healthcare professionals involved in psychiatric research and psychiatric care.
In the U.S., Lundbeck is partnering with Takeda Global Research and Development Center Inc., U.S. on the co-development and co-commercialization of this compound. There are currently four ongoing short-term depression studies and two long-term safety studies.
